Satya is at BIO, 2023 – Boston, June 3-6
Satya is attending the BIO at Boston during June 3-6, 2023. Please also visit the India Pavilion with an exhibit of Satya’s poster and pipeline
news-events
Satya chosen as one of the top Promising startups at BIO ASIA 2023
BIO ASIA 2023 held in February 2023 Satya is chosen as one of the most promising startups at the recent BIO ASIA 2023 held in February 2023 at Hyderabad. The award was received by Murthy Chavali from the Hon. Minister for Urban Development and Municipal Administration, Government of Telangana.
Satya is at JPM 2023
Please set up a meeting with CSN at murthycsn@satyarx.com
Satya’s MedChem leadership expanded
Navnath Karche, PhD, a Medicinal Chemist with over 18 years of experience across multiple discovery programs in Oncology, Metabolic Disorders, and CNS therapeutic areas. Navnath previously worked at Dai-Ichi and Lupin, after his PhD from Pune University and post-doc from Rouen, France. Ganesh Gudade, with over 20 years of MedChem experience at Lupin, Glenmark and …
Satya strengthens Scientific team
Srikant Viswanadha, an accomplished industry leader, has joined Satya as its CSO. Srikant has over 19 years’ pharmaceutical experience in reputed companies, and has been involved in the discovery and early clinical development of multiple programs. He was last the CSO at Incozen/ Rhizen. Manoj Pothuganti has also joined Satya as a Program Lead and …
Satya at ASCO Annual Meeting, Chicago June 3-6, 2022.
Satya is attending the ASCO Annual Meeting between June 3-6, 2022 at Chicago, IL.
Satya expands lab infrastructure
Satya is expanding its lab infrastructure and team size at its facilities in Hyderabad, India to add additional discovery programs to the pipeline. Upon completion, the lab size would double and the company can run up to six discovery programs in parallel.
Satya presents 2 e-posters at the AACR Annual Meeting
Poster 6368: “Discovery of potent, orally bioavailable, SOS1 inhibitors for KRAS-driven tumors” Abstract KRAS is an oncogene implicated in a wide variety of tumors (~21% of solid tumors harbor KRAS mutations). KRAS interaction with Guanidine Exchange Factors (GEFs) is crucial for its activation, with SOS1 being the predominant GEF. SOS1 inhibition is thus expected …
Satya presents 2 e-posters at the AACR Annual Meeting Read More »
Satya presents poster on its RAD51-BRCA2 disruptor program at AACR, New Orleans April 8-13
Poster #LBA041: AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer, October 7-10, 2021 The DNA damage response (DDR) is a complex cellular network that acts as a cell defense mechanism and exerts signal for repair of DNA lesions. It repairs different types of DNA damage such as single-strand (ssDNA) breaks, DNA inter-strand crosslinks and …
Satya takes incubation space at AIC-CCMB
Satya has taken incubation space at the AIC-CCMB campus in Hyderabad; the incubation space provides access to world-class biology infrastructure, as well as expertise available at CCMB, a premier biology institution of India Satya will have its senior scientists working out of the incubation centre, and would be able to conduct a number of advanced …
